Butylamine

Butylamine

SCHEMBL17784256

CCCCN.O=P(O)(O)O.[NaH]

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Butylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GABBR2 O75899 3/20 0.62
GABBR1 Q9UBS5 3/20 0.62
GABRR1 P24046 1/20 0.62
FDPS P14324 3/20 0.50
TSHR P16473 2/20 0.50
CYP1A2 P05177 1/20 0.50
THPO P40225 1/20 0.50
LMNA P02545 2/20 0.48
BLM P54132 2/20 0.48
CYP3A4 P08684 1/20 0.48
NFKB1 P19838 1/20 0.48
PMP22 Q01453 1/20 0.48
DNM1 Q05193 4/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ALDH1A1 P00352 1/20 0.48
EPHX1 P07099 1/20 0.48
SMPD1 P17405 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butylamine SCHEMBL4299245 0.97 GABBR2 (0.65) GABBR2GABBR1GABRR1FDPSTSHR
Butylamine SCHEMBL728279 0.97 GABBR2 (0.65) GABBR2GABBR1GABRR1FDPSTSHR
Butylamine SCHEMBL21981126 0.97 GABBR2 (0.65) GABBR2GABBR1GABRR1FDPSTSHR
Butylamine SCHEMBL29194903 0.94 GABBR2 (0.62) GABBR2GABBR1GABRR1FDPSTSHR
Butylamine SCHEMBL28755797 0.94 GABBR2 (0.62) GABBR2GABBR1GABRR1FDPSTSHR
Dodecylamine SCHEMBL29217560 0.90 DNM1 (0.65) GABBR2GABBR1GABRR1FDPSTSHR
Phosphoric Acid SCHEMBL30479420 0.89 DNM1 (0.63) GABBR2GABBR1GABRR1FDPSTSHR
Phosphoric Acid SCHEMBL1537957 0.89 DNM1 (0.63) GABBR2GABBR1GABRR1FDPSTSHR
Butylamine SCHEMBL10437182 0.89 GABBR2 (0.62) GABBR2GABBR1GABRR1FDPSTSHR
Butylamine SCHEMBL28113446 0.87 GABBR2 (0.56) GABBR2GABBR1GABRR1FDPSTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105983426-B Amorphous calcium phosphate catalyst for production of 1, 3-butadiene and methyl ethyl ketone from 2, 3-butanediol, and method for preparation thereof SK新技术株式会社 2020-11-17 CN disclosed
EP-3053650-B1 Method for preparing an amorphous calcium phosphate catalyst, and its use in production of 1,3-butadiene and methyl ethyl ketone starting from 2,3-butanediol SK INNOVATION CO LTD (KR) 2019-06-05 EP disclosed
US-9884800-B2 Method of preparing 1,3-butadiene and methyl ethyl ketone from 2,3-butanediol using adiabatic reactor SK INNOVATION CO., LTD. (KR) 2018-02-06 US disclosed
US-20170342009-A1 METHOD OF PREPARING 1,3-BUTADIENE AND METHYL ETHYL KETONE FROM 2,3-BUTANEDIOL USING ADIABATIC REACTOR SK INNOVATION CO., LTD. (KR) 2017-11-30 US disclosed
US-9511357-B2 Amorphous calcium phosphate catalyst for use in production of 1,3-butadiene and methyl ethyl ketone from 2,3-butanediol, and method of preparing the same SK INNOVATION CO., LTD. (KR) 2016-12-06 US disclosed
EP-3053650-A1 Amorphous calcium phosphate catalyst,its use in production of 1,3-butadiene and methyl ethyl ketone from 2,3-butanediol, and method of preparing the same SK Innovation Co., Ltd. (KR) 2016-08-10 EP disclosed
US-20160151769-A1 AMORPHOUS CALCIUM PHOSPHATE CATALYST FOR USE IN PRODUCTION OF 1,3-BUTADIENE AND METHYL ETHYL KETONE FROM 2,3-BUTANEDIOL, AND METHOD OF PREPARING THE SAME SK GEO CENTRIC CO., LTD. (KR) 2016-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160151769-A1 AMORPHOUS CALCIUM PHOSPHATE CATALYST FOR USE IN PRODUCTION OF 1,3-BUTADIENE AND METHYL ETHYL KETONE FROM 2,3-BUTANEDIOL, AND METHOD OF PREPARING THE SAME CACYBP, BCKDK, PHKA2 GABBR2 1916/4885GABBR1 1856/4885GABRR1 2012/4885
US-20170342009-A1 METHOD OF PREPARING 1,3-BUTADIENE AND METHYL ETHYL KETONE FROM 2,3-BUTANEDIOL USING ADIABATIC REACTOR ADH1C, AKR1D1, ADH1A GABBR2 1643/4885GABBR1 1897/4885GABRR1 1169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.